The effects of allopurinol treatment on mortality among patients with gout remain uncertain, with a new meta-analysis finding conflicting results. In a systematic review of the literature that ...

Please provide your email address to receive an email when new articles are posted on . Allopurinol is noninferior to febuxostat for gout when dosed appropriately as part of a treat-to-target strategy ...

Please provide your email address to receive an email when new articles are posted on . “A meta-analysis of randomized controlled trials reporting on the comparison of allopurinol or oxypurinol with ...

Among patients with gout, allopurinol use is associated with a lower risk for urolithiasis compared with benzbromarone. Among patients with gout, allopurinol use is associated with a lower risk for ...

The comparative efficacy of these therapies has been extended to patients with stage 3 chronic kidney disease, a common comorbidity in gout. Allopurinol and febuxostat are similarly effective in ...

BARCELONA, Spain—The gout drug allopurinol on top of usual care does not improve cardiovascular outcomes in patients over age 60 who do not have gout, the ALL-HEART trial confirms. The long-running ...

*Refers to the latest 2 years of stltoday.com stories. Cancel anytime. Dear Dr. Roach • I got a call from my internist that my blood test showed an elevated uric acid and I would need to start ...

Credit: Shutterstock. The investigational drug AR882 appeared more effective and safer than allopurinol monotherapy in a phase 2 trial. A novel selective URAT1 inhibitor, AR882, further reduces serum ...

Allopurinol treatment is not associated with increased mortality in patients with gout and chronic kidney disease even at 5 years after starting treatment, a study has found. Around 1 in 5 patients ...

For gout, xanthine oxidase (XO) inhibitors are the choice for first-line urate-lowering therapy (ULT) according to the 2020 American College of Rheumatology Guideline for the Management of Gout, which ...

Results from the University of New South Wales appeared in the New England Journal of Medicine. The co-lead investigator said the results show the need for more treatment options in chronic kidney ...